Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.25 (1.79%)
Spread: 0.50 (3.571%)
Open: 14.00
High: 14.75
Low: 14.00
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Snr Appt at Geomerics

16 Dec 2005 14:32

Angle PLC16 December 2005 For Immediate Release 16 December 2005 ANGLE plc ("ANGLE" or the "Company") SENIOR APPOINTMENT; GEOMERICS LTD ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce the appointment of Julian Davis, as Chief TechnologyOfficer at venture company, Geomerics Ltd. Davis, who joins from Kuju Entertainment, the publicly listed computer gamescompany where he held the position of Technical Director for the past six years,has been an active participant on the Microsoft Graphics and Xbox advisoryboards and is highly regarded for his videogame industry knowledge andexperience. Commenting on his appointment, Davis said: "I am delighted to be joining Geomerics. I am confident that the technology willrevolutionise the way video games are made and will offer substantial advantagesand benefits to developers and publishers of next generation titles." Dr Chris Doran, CEO of Geomerics added, "There is no doubt that Julian is an industry heavyweight and will be a valuableasset to us. Geomerics' technology is advancing quickly and we are confident ithas the capacity to greatly impact this industry in the near future. Julian'sexperience and advice will be invaluable in our drive towards commercialisation.We are truly excited to have him on board." Founded earlier this year, Geomerics has secured intellectual property in the field of geometric algebra, a powerful new form of mathematics that vastly simplifies complex geometric calculations. Geometric algebra has its origins in the rather esoteric academic discipline of theoretical cosmology, but it has nowbeen developed for application in a wide variety of disparate commercial applications such as computer graphics in computer games and electromagnetic modelling which is used, amongst other things, for optimising the design of mobile phone antennas and reducing the radar signature of ships and planes. Geomerics' technology provides a major step-change improvement over thecompetition, and is set to revolutionise the market. Overall the market forcomputer games is currently worth more than $30bn and growing rapidly, and themarket for graphics within these games is worth over $600m per year. Since itsestablishment, Geomerics has developed a suite of impressive demonstrationswhich have attracted considerable interest in early customer meetings. Geomerics is an ANGLE Progeny(R) Company. For further information ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director - New Ventures Geomerics Ltd 01223 370030Dr Chris Doran, Chief Executive Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting
21st Oct 20226:15 pmRNSIssue of Equity
18th Oct 20227:00 amRNSStreamlining of operations to increase cash runway
17th Oct 20222:23 pmRNSTR-1: Notification of major holdings
12th Oct 20227:00 amRNSFirst regional distribution agreement
30th Sep 20225:30 pmRNSIssue of Equity
30th Sep 20225:30 pmRNSHolding(s) in Company
29th Sep 20227:00 amRNSInterim Results
29th Sep 20227:00 amRNSPositive headline results from ovarian study
28th Sep 20227:00 amRNSStudy using Parsortix in head and neck cancer
13th Sep 20227:00 amRNSNew poster presented at ASCP Meeting
12th Sep 20227:30 amRNSNovel assay predicts malignancy in pelvic mass
1st Sep 20227:00 amRNSNotice of Interim Results and Webcast
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.